Navigation Links
Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Date:3/26/2013

CHARLOTTESVILLE, Virginia und CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ --

DART Therapeutics Inc., ein innovatives Biotechnologie-Unternehmen neuester Art, das sich auf die Entwicklung von Therapien für die Duchenne-Muskeldystrophie (DMD) konzentriert, und Biovista, ein führender Anbieter für die systematische Neupositionierung von Medikamenten, gaben heute bekannt, dass sie eine Forschungskooperation eingegangen sind, um neuartige Kandidaten für die Neupositionierung von Medikamenten für DMD zu identifizieren und zu entwickeln, wobei die Biovista-Technologie "Clinical Outcome Search Space" (COSS) ™ genutzt werden soll. Gemäß der Vereinbarung wird Biovista neuartige Kandidaten für die Neupositionierung identifizieren und die Firma DART Therapeutics wird die Möglichkeit haben, eine bestimmte Anzahl für die weitere Entwicklung auszuwählen. Die Bedingungen der Vereinbarung umfassen eine Vorauszahlung und nachgeschaltete erfolgsabhängige Zahlungen.

"Die Neupositionierung von Medikamenten ist ein wichtiger Ansatz in unserer Gesamtstrategie zur möglichst effizienten Identifikation neuartiger Behandlungsmethoden für DMD", sagte Gene Williams , Chief Executive Officer von DART Therapeutics. "Biovista und die COSS-Technologie sind führend in der systematischen Neupositionierung und gewährleisten uns die breitestmögliche Abdeckung aller Möglichkeiten der Neupositionierung, die wirklich starke Auswirkungen auf Patienten und ihre Familien haben können, die auf eine Behandlung für DMD warten."

"Das Unternehmen DART Therapeutics steht für ein einzigartiges Modell, das den Entwicklungsarm einer großen Interessengruppe von Patienten darstellt. Die Führungsrolle des Unternehmens bei DMD ist eine ausgezeichnete Ergänzung zu unseren eigenen F
'/>"/>

SOURCE Biovista, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 The ... the nation’s leading nonprofit authority on the use ... information exchange, announces its appointment of four new ... The workgroup leaders include:, ,     Peter ...     Erik Pupo, Specialist Leader, Deloitte Consulting LLP ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 SonaCare ... focused ultrasound (HIFU) technology, announced that its Board ... as Chief Executive Officer, President and member of ... Dr. Carol will take-on expanded responsibilities within the ... as well as overseeing commercialization, manufacturing and finance. ...
(Date:10/25/2014)... , October 24, 2014 ... clinical-stage pharmaceutical company focused on the development of oral ... Nadav Kidron will present at FireRock Capital,s ... Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ... New York City , ...
(Date:10/25/2014)... -- Investor-Edge has initiated coverage on the ... Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), Alexion ... Inc. (NASDAQ: PPHM ), and StemCells Inc. ... be accessed at: http://investor-edge.com/register . The ... a positive note as the Dow Jones Industrial Average ...
Breaking Biology Technology:WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5
... for Combining Efficiency and Renewables into an Energy ... recognized as an important component to America' energy ... discussion about including Energy Efficiency into what many ... Standards (RPS) . The whole idea being that ...
... Merge eFilm announced Wednesday that its net income ... same quarter last year. Though its net sales, at ... bottom line suffered because it paid more than twice ... quarter ending June 30 were $1,497,000, up from $1,400,000 ...
... partnership to provide travel solution , ,ROCHESTER, ... Concur Technologies, Inc. announced Monday the formation ... that will deliver benchmarking information to travel managers ... Runzheimer, an international consulting firm specializing in travel ...
Cached Biology Technology:Energy efficiency is no longer the Rodney Dangerfield of energy 2Energy efficiency is no longer the Rodney Dangerfield of energy 3Runzheimer and Concur develop travel management service 2
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
(Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... -- Scientists from The Forsyth Institute and Kings College, ... community, the Human Oral Microbiome Database, which provides descriptions ... commonly found in peoples mouths. Most bacteria living ... maintaining the health of teeth and gums, as well ...
... a biosensing nanodevice developed by Arizona State University ... airport security checkpoints and revolutionize health screenings for ... aureus (MRSA). Even more incredible than the ... the worlds tiniest rotary motor: a biological engine ...
... ... covert data -, LAKE WORTH, Fla., March 24 ... produce the,world,s first self-authenticating passport. It was introduced in the new,Belgian passport ... produces the Belgian passport,has added an optical decoder page in the passport ...
Cached Biology News:Scientists launch human oral microbiome database 2Biosensing nanodevice to revolutionize health screenings 2Biosensing nanodevice to revolutionize health screenings 3FCO and GSSC Team to Create World's First Self-Authenticating Passport 2
... work in collaboration with Pall Life Sciences ... in a variety of membrane chemistries. The ... on the Caliper TPWII, MultiDose, Prelude, and ... our Automation Certified Syringe Filters are available ...
... The Mini-PROTEAN 3 Dodeca cell with multi-casting ... of up to 12 mini format handcast (8.3 ... cm) gels. The cell requires 3.4-4.4 L of ... cooling coil that attaches to an external refrigerated ...
...
... has been developed to significantly increase the ... Stability is increased at room temperature ... This product is subjected to 0.2 ... azide. This formulation insures consistently high ...
Biology Products: